Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of “Moderate Buy” by Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $17.13.

A number of equities research analysts recently issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Morgan Stanley dropped their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Bank of America lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. dropped their price target on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Hazlett Burt & Watson Inc. increased its holdings in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the period. Blue Trust Inc. increased its holdings in Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares during the period. Arcadia Investment Management Corp MI purchased a new position in Amicus Therapeutics during the 3rd quarter valued at about $32,000. Headlands Technologies LLC purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $89,000. Finally, Sage Capital Advisors llc purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $103,000.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $11.42 on Friday. Amicus Therapeutics has a one year low of $9.02 and a one year high of $14.57. The business has a fifty day moving average price of $11.16 and a 200-day moving average price of $10.57. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26. The firm has a market capitalization of $3.39 billion, a P/E ratio of -29.28 and a beta of 0.69.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The company had revenue of $126.67 million for the quarter, compared to the consensus estimate of $121.21 million. During the same quarter last year, the business posted ($0.15) earnings per share. The firm’s revenue was up 34.0% compared to the same quarter last year. As a group, equities research analysts forecast that Amicus Therapeutics will post -0.06 EPS for the current year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.